Ono Pharmaceutical Co., Ltd. (OPHLF)
USD 10.89
(0.0%)
USD 10.89
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 502.67 Billion JPY | 12.41% |
| 2023 | 447.18 Billion JPY | 23.75% |
| 2022 | 361.36 Billion JPY | 16.84% |
| 2021 | 309.28 Billion JPY | 5.77% |
| 2020 | 292.42 Billion JPY | 1.31% |
| 2019 | 288.63 Billion JPY | 10.23% |
| 2018 | 261.83 Billion JPY | 6.96% |
| 2017 | 244.79 Billion JPY | 52.73% |
| 2016 | 160.28 Billion JPY | 18.05% |
| 2015 | 135.77 Billion JPY | -5.22% |
| 2014 | 143.24 Billion JPY | -1.48% |
| 2013 | 145.39 Billion JPY | -0.26% |
| 2012 | 145.77 Billion JPY | 7.78% |
| 2011 | 135.25 Billion JPY | -0.54% |
| 2010 | 135.98 Billion JPY | -0.42% |
| 2009 | 136.55 Billion JPY | -6.4% |
| 2008 | 145.89 Billion JPY | 2.95% |
| 2007 | 141.71 Billion JPY | -4.68% |
| 2006 | 148.67 Billion JPY | 2.32% |
| 2005 | 145.3 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q4 | 112.76 Billion JPY | -14.04% |
| 2024 Q1 | 120.01 Billion JPY | 10.95% |
| 2024 Q3 | 131.19 Billion JPY | -5.41% |
| 2024 FY | 502.67 Billion JPY | 12.41% |
| 2024 Q2 | 138.69 Billion JPY | 15.57% |
| 2023 Q4 | 108.16 Billion JPY | -11.57% |
| 2023 Q2 | 109.97 Billion JPY | 3.05% |
| 2023 Q1 | 106.72 Billion JPY | 18.67% |
| 2023 FY | 447.18 Billion JPY | 23.75% |
| 2023 Q3 | 122.31 Billion JPY | 11.22% |
| 2022 Q3 | 97.35 Billion JPY | 12.27% |
| 2022 Q4 | 89.93 Billion JPY | -7.62% |
| 2022 FY | 361.36 Billion JPY | 16.84% |
| 2022 Q1 | 87.36 Billion JPY | 17.5% |
| 2022 Q2 | 86.71 Billion JPY | -0.74% |
| 2021 Q2 | 75.56 Billion JPY | 0.87% |
| 2021 Q1 | 74.91 Billion JPY | 11.61% |
| 2021 FY | 309.28 Billion JPY | 5.77% |
| 2021 Q4 | 74.35 Billion JPY | -11.97% |
| 2021 Q3 | 84.45 Billion JPY | 11.78% |
| 2020 Q3 | 76.29 Billion JPY | 1.69% |
| 2020 FY | 292.42 Billion JPY | 1.31% |
| 2020 Q4 | 67.12 Billion JPY | -12.02% |
| 2020 Q2 | 75.02 Billion JPY | 1.41% |
| 2020 Q1 | 73.98 Billion JPY | 13.06% |
| 2019 Q2 | 73.15 Billion JPY | 2.68% |
| 2019 Q3 | 78.8 Billion JPY | 7.72% |
| 2019 FY | 288.63 Billion JPY | 10.23% |
| 2019 Q4 | 65.43 Billion JPY | -16.96% |
| 2019 Q1 | 71.24 Billion JPY | 16.28% |
| 2018 Q4 | 61.26 Billion JPY | -22.57% |
| 2018 Q3 | 79.12 Billion JPY | 30.71% |
| 2018 Q2 | 60.53 Billion JPY | -0.62% |
| 2018 Q1 | 60.91 Billion JPY | 8.87% |
| 2018 FY | 261.83 Billion JPY | 6.96% |
| 2017 Q4 | 55.95 Billion JPY | -21.33% |
| 2017 FY | 244.79 Billion JPY | 52.73% |
| 2017 Q2 | 58.96 Billion JPY | 0.36% |
| 2017 Q1 | 58.75 Billion JPY | 22.76% |
| 2017 Q3 | 71.11 Billion JPY | 20.6% |
| 2016 Q4 | 47.86 Billion JPY | 13.65% |
| 2016 Q1 | 35.69 Billion JPY | 25.21% |
| 2016 Q2 | 34.6 Billion JPY | -3.05% |
| 2016 FY | 160.28 Billion JPY | 18.05% |
| 2016 Q3 | 42.11 Billion JPY | 21.69% |
| 2015 Q2 | 30.57 Billion JPY | -3.88% |
| 2015 FY | 135.77 Billion JPY | -5.22% |
| 2015 Q4 | 28.5 Billion JPY | -36.49% |
| 2015 Q3 | 44.88 Billion JPY | 46.82% |
| 2015 Q1 | 31.8 Billion JPY | 4.89% |
| 2014 FY | 143.24 Billion JPY | -1.48% |
| 2014 Q2 | 33.79 Billion JPY | -10.86% |
| 2014 Q3 | 41.22 Billion JPY | 21.98% |
| 2014 Q4 | 30.32 Billion JPY | -26.43% |
| 2014 Q1 | 37.9 Billion JPY | 14.79% |
| 2013 Q3 | 41.25 Billion JPY | 23.31% |
| 2013 FY | 145.39 Billion JPY | -0.26% |
| 2013 Q1 | 37.65 Billion JPY | 14.12% |
| 2013 Q4 | 33.02 Billion JPY | -19.96% |
| 2013 Q2 | 33.45 Billion JPY | -11.14% |
| 2012 Q4 | 32.99 Billion JPY | -22.58% |
| 2012 Q3 | 42.61 Billion JPY | 25.92% |
| 2012 Q2 | 33.84 Billion JPY | -6.84% |
| 2012 Q1 | 36.32 Billion JPY | 7.97% |
| 2012 FY | 145.77 Billion JPY | 7.78% |
| 2011 Q1 | 33.83 Billion JPY | 14.06% |
| 2011 Q2 | 29.94 Billion JPY | -11.48% |
| 2011 Q4 | 33.64 Billion JPY | -11.06% |
| 2011 FY | 135.25 Billion JPY | -0.54% |
| 2011 Q3 | 37.83 Billion JPY | 26.33% |
| 2010 Q1 | 36.44 Billion JPY | 12.84% |
| 2010 FY | 135.98 Billion JPY | -0.42% |
| 2010 Q2 | 30.73 Billion JPY | -15.67% |
| 2010 Q3 | 39.14 Billion JPY | 27.35% |
| 2010 Q4 | 29.66 Billion JPY | -24.22% |
| 2009 FY | 136.55 Billion JPY | -6.4% |
| 2009 Q2 | 30.33 Billion JPY | 0.0% |
| 2009 Q4 | 32.3 Billion JPY | -15.57% |
| 2009 Q3 | 38.26 Billion JPY | 26.13% |
| 2008 FY | 145.89 Billion JPY | 2.95% |
| 2007 FY | 141.71 Billion JPY | -4.68% |
| 2006 FY | 148.67 Billion JPY | 2.32% |
| 2005 FY | 145.3 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | -971.46% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | -1016.9% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | -1498.316% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -3601476.27% |
| Novartis AG | 46.66 Billion USD | -977.308% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -25297.817% |